A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s immune system to generate protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% protection when immunised four weeks before birth
- Antibodies from the mother transferred through the placenta safeguard newborns from birth
- Protection achievable with 2-week gap before premature birth
- Vaccination in the third trimester still offers meaningful protection for infants
Strong evidence from recent research
The performance of the pregnancy RSV vaccine has been confirmed through a thorough investigation undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that half-year window, providing strong and reliable information of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scale of this research offers healthcare professionals and expectant parents with confidence in the vaccine’s proven efficacy across varied populations and settings.
The results present a striking picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This marked difference underscores the vaccine’s critical role in reducing the risk of serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Methodology and scope of study
The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospital admissions. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology captured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine performs when given across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its dangers
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection triggers inflammation deep within the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed effectively. Parents often witness their babies visibly struggling, their chests rising whilst they try to pull sufficient oxygen into their compromised lungs. Whilst the majority of babies recover with clinical support, a small but significant number die from respiratory syncytial virus complications yearly, making vaccination as prevention a vital health service priority for protecting the most vulnerable and youngest people in our communities.
- RSV produces inflammation in lungs, leading to serious respiratory problems in infants
- Nearly 50% of infants catch the virus in their first few months of life
- Symptoms range from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV each year
- Small numbers of infants succumb to RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the significance of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery delivers nearly 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies through the placenta.
The communication from public health bodies stays clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among eligible pregnant women, whilst others remain focused to increase awareness and availability of the jab. These geographical variations reflect differences across healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics shows robust and reliable protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to reach women during pregnancy
- Regional disparities in vaccine uptake rates throughout England demand focused enhancement
- Local healthcare systems adapting programmes to align with community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness translates into tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the rollout of this protective measure, the 80% decrease in admissions means thousands of infants protected against critical disease. Parents no more face the distressing scenario of seeing their babies labour to breathe or difficulty feeding, symptoms that characterise serious RSV disease. The vaccine has markedly changed the picture of neonatal respiratory health, giving expectant mothers a active means to shield their most vulnerable children during those vital initial period.
For families like that of Malachi, whose serious RSV infection caused profound brain damage, the vaccine’s introduction carries deep personal significance. His mother’s support of the jab emphasises the life-altering consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to women in pregnancy navigating their late pregnancy, transforming what was once an unavoidable seasonal threat into a controllable health concern.